Difficulty: Medium
Average Score: 82%
Practice
Which of the following is a PCSK9 inhibitor?
Correct answer
B
Rationale
B' is correct because evolocumab is a PCSK9 inhibitor, increasing LDL receptor activity, per pharmacology. 'A' (evinacumab) targets ANGPTL3. 'C' (volanesorsen) and 'D' (vupanorsen) affect TG. Evolocumab's PCSK9 specificity lowers LDL potently.